Skip to main content
Premium Trial:

Request an Annual Quote

US Genomics Changes Name to Pathogenetix, Raises $1.3M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – US Genomics has raised $1.3 million in a private financing and sold $900,000 in debt instruments, the company disclosed in separate documents filed with the US Securities and Exchange Commission this week.

The Woburn, Mass.-based firm has also changed its name to Pathogenetix.

The company did not identify investors on either transaction but listed related persons that include Augustine Lawlor, a managing partner at HealthCare Ventures, Steve Gullans, a managing director at Excel Venture Management, and Enrico Petrillo, also a managing director at Excel Venture Management. The three are also directors of Pathogenetix.

The company did not say how the funds will be used but said it is not in connection with a business combination, such as a merger, acquisition, or exchange offer.

In its filing outlining the $900,000 debt conversion, Pathogenetix said another $300,000 in that offering remains unsold. The company said in January that it had raised $1 million through a sale of equity and debt securities.

US Genomics was founded in 1997 and had focused its genomic mapping technology on identifying and quantifying DNA, RNA, and proteins in complex samples. It is unclear why it changed its name or how the business model may have changed.

A call to the firm was not returned by the time this article was published.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more